Biologics : Targets & Therapy最新文献_第10页

Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. 肺结核和病毒性肝炎感染在东欧、亚洲和拉丁美洲:肿瘤坏死因子-α抑制剂在临床实践中的影响

IF 4

Biologics : Targets & Therapy Pub Date : 2018-01-12 eCollection Date: 2018-01-01 DOI: 10.2147/BTT.S148606

Yi-Hsing Chen, Hellen Mds de Carvalho, Umut Kalyoncu, Lyndon John Q Llamado, Gaston Solano, Ron Pedersen, Galina Lukina, Juan J Lichauco, Radu S Vasilescu

{"title":"Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice.","authors":"Yi-Hsing Chen, Hellen Mds de Carvalho, Umut Kalyoncu, Lyndon John Q Llamado, Gaston Solano, Ron Pedersen, Galina Lukina, Juan J Lichauco, Radu S Vasilescu","doi":"10.2147/BTT.S148606","DOIUrl":"https://doi.org/10.2147/BTT.S148606","url":null,"abstract":"Tumor necrosis factor-α (TNF-α) inhibitors are increasingly becoming the standard of care for treating a number of inflammatory diseases. However, treatment with TNF-α inhibitors carries an inherent risk of compromising the immune system, resulting in an increased susceptibility to infections and malignancies. This increased risk of infection is of particular concern in Asia, Eastern Europe, and Latin America where tuberculosis (TB) and viral hepatitis are endemic. In this brief review, we examine the literature and review the impact of TNF-α inhibitors on the incidence and the reactivation of latent disease with respect to TB, hepatitis C infection, and hepatitis B infection. Our findings show that TNF-α inhibitors are generally safe, if used with caution. Patients should be screened prior to the initiation of TNF-α inhibitor treatment and given prophylactic treatment if needed. In addition, patients should be monitored during treatment with TNF-α inhibitors and after treatment has stopped to ensure that infections, if detected, are treated promptly and effectively. Our analysis is consistent with other reports and guidelines.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"12 ","pages":"1-9"},"PeriodicalIF":4.0,"publicationDate":"2018-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S148606","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35785952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Anti-angiogenic effects of biotechnological therapies in rheumatic diseases. 生物技术治疗在风湿病中的抗血管生成作用。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-12-14 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S143674

Francesco Paolo Cantatore, Nicola Maruotti, Addolorata Corrado, Domenico Ribatti

引用次数: 10

Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. 奥曲肽治疗神经内分泌肿瘤的长效可重复性:患者选择及展望。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-12-06 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S108818

Hanford Yau, Mustafa Kinaan, Suzanne L Quinn, Andreas G Moraitis

{"title":"Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.","authors":"Hanford Yau, Mustafa Kinaan, Suzanne L Quinn, Andreas G Moraitis","doi":"10.2147/BTT.S108818","DOIUrl":"https://doi.org/10.2147/BTT.S108818","url":null,"abstract":"Over the past three decades, the incidence and prevalence of neuroendocrine tumors have gradually increased. Due to the slow-growing nature of these tumors, most cases are diagnosed at advanced stages. Prognosis and survival are associated with location of primary lesion, biochemical functional status, differentiation, initial staging, and response to therapy. Octreotide, the first synthetic somatostatin analog, was initially used for the management of gastrointestinal symptoms associated with functional carcinoid tumors. Its commercial development over time led to long-acting repeatable octreotide acetate, a long-acting version that provided greater administration convenience. Recent research demonstrates that octreotide's efficacy has evolved beyond symptomatic management to targeted therapy with antitumoral effects. This review examines the history and development of octreotide, provides a synopsis on the classification, grading, and staging of neuroendocrine tumors, and reviews the evidence of long-acting repeatable octreotide acetate as monotherapy and in combination with other treatment modalities in the management of non-pituitary neuroendocrine tumors with special attention to recent high-quality Phase III trials.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"11 ","pages":"115-122"},"PeriodicalIF":4.0,"publicationDate":"2017-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S108818","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35668777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Anticholinesterase constituents from the leaves of Spondias mombin L. (Anacardiaceae). Spondias mombin L.（洋金花科）叶片中的抗胆碱酯酶成分。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-08-02 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S136011

Taiwo Olayemi Elufioye, Efere M Obuotor, Joseph M Agbedahunsi, Saburi A Adesanya

{"title":"Anticholinesterase constituents from the leaves of Spondias mombin L. (Anacardiaceae).","authors":"Taiwo Olayemi Elufioye, Efere M Obuotor, Joseph M Agbedahunsi, Saburi A Adesanya","doi":"10.2147/BTT.S136011","DOIUrl":"10.2147/BTT.S136011","url":null,"abstract":"Spondias mombin has been used in traditional medicine for the management of several diseases, including memory loss. This study aimed to evaluate the cholinesterase inhibitory activity of the methanol extract of the leaves and its derived fractions, as well as carry out detailed phytochemical investigations leading to the isolation and characterization of bioactive compounds from the plant. The acetyl cholinesterase (AChE) and butyryl cholinesterase (BUChE) inhibitory activities were evaluated by colorimetric and thin-layer chromatography bioautographic assay techniques. The ethyl acetate fraction was most active against both enzymes, with percentage inhibition of 58.10 ± 1.08% and 52.66 ± 1.34% against AChE and BUChE, respectively. Three compounds, namely, botulin, campesterol and phytol, with IC50 of 0.88 μg/mL (AChE), 4.67 μg/mL (BuChE); 1.89 μg/mL (AChE), 4.08 μg/mL (BuChE) and 12.51 μg/mL (AChE), 23.89 μg/mL (BuChE), respectively, were isolated from the supernatant of the ethyl acetate fraction. The isolated cholinesterase inhibitory compounds correlate with the known memory-enhancing property of the plant and thus support one of its uses in ethnomedicine.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"11 ","pages":"107-114"},"PeriodicalIF":4.0,"publicationDate":"2017-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/0b/btt-11-107.PMC5546590.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35419815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epigenetic memory of oxidative stress: does nephrilin exert its protective effects via Rac1? 氧化应激的表观遗传记忆:肾上腺素是否通过Rac1发挥保护作用?

IF 4

Biologics : Targets & Therapy Pub Date : 2017-07-17 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S136188

Desmond D Mascarenhas, David N Herndon, Istvan Arany

{"title":"Epigenetic memory of oxidative stress: does nephrilin exert its protective effects via Rac1?","authors":"Desmond D Mascarenhas, David N Herndon, Istvan Arany","doi":"10.2147/BTT.S136188","DOIUrl":"https://doi.org/10.2147/BTT.S136188","url":null,"abstract":"Aim: Nephrilin peptide, a designed inhibitor of Rictor complex (mTORC2), exerts pleiotropic protective effects in metabolic, xenobiotic and traumatic stress models. Stress can generate enduring epigenetic changes in gene function. In this work we examine the possibility that nephrilin treatment protects against acute and enduring global changes in oxidative metabolism, with a focus on the Rictor-complex-mediated activation of Rac1, a subunit of NADPH oxidase (Nox) via PKCs, Prex1 and p66shc.Methods: Given the wide range of animal models in which nephrilin peptide has previously demonstrated effectiveness in vivo, we chose three different experimental systems for this investigation: dermal fibroblasts, renal proximal tubule epithelial cells (PTECs), and kidney tissue and urine from an animal model of burn trauma in which nephrilin was previously shown to prevent loss of kidney function.Results: (1) Nephrilin protects dermal fibroblasts from loss of viability and collagen synthesis after ultraviolet A (UV-A) or H2O2 insult. (2) Nephrilin reduces reactive oxygen species (ROS) formation by H2O2-treated (PTECs) with or without nicotine pretreatment. Using RNA arrays and pathway analysis we demonstrate that nicotine and H2O2-treated PTECs specifically induced Rac1 gene networks in these cells. (3) Using kidney tissue and urine from the burn trauma model we demonstrate significant elevations of [a] 8-aminoprostane in urine; [b] kidney tissue histone modification and DNA methylation; and [c] post-transcriptional phosphorylation events consistent with Rac1 activation in kidney tissue.Conclusion: Nephrilin protects against oxidative stress, possibly by modulating the activation of Rac1.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"11 ","pages":"97-106"},"PeriodicalIF":4.0,"publicationDate":"2017-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S136188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35368728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. mepolizumab在重度嗜酸性哮喘中的患者概况和临床应用。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-06-27 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S93954

Pranabashis Haldar

{"title":"Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma.","authors":"Pranabashis Haldar","doi":"10.2147/BTT.S93954","DOIUrl":"https://doi.org/10.2147/BTT.S93954","url":null,"abstract":"Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently National Institute for Health and Care Excellence (NICE; UK). It is one of several molecular therapies in development for this indication and is illustrative of the strategic trajectory for pharmaceutical drug development taken over the past decade in several disease areas. Molecular therapies offer the prospect of improved specificity and effectiveness of biological effect. However, this necessitates a clear understanding of the underlying mechanistic pathways underpinning pathological processes, to inform drug development that yields novel more efficacious treatment options with a better clinical profile than existing agents. For the first time, utilization of molecular therapies in clinical trials is providing a novel in vivo model to characterize the association between specific pathways and clinical disease expression. It is increasingly recognized that asthma exhibits both clinical and pathological heterogeneity. It follows that a one-size-fits-all approach will not be appropriate and cost-effectiveness may only be achieved by identifying responder subgroups. This so-called personalized approach to therapy is being supported by the parallel development of companion biomarkers for clinical application. In this review, the author summarizes the clinical studies, their interpretation and the lessons learnt with mepolizumab that have informed our understanding of the approach to personalized molecular therapy in asthma.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"11 ","pages":"81-95"},"PeriodicalIF":4.0,"publicationDate":"2017-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S93954","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35179759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Autophagy regulates the stemness of cervical cancer stem cells. 自噬调节子宫颈癌干细胞的干性。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-06-21 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S134920

Yi Yang, Li Yu, Jin Li, Ya Hong Yuan, Xiao Li Wang, Shi Rong Yan, Dong Sheng Li, Yan Ding

{"title":"Autophagy regulates the stemness of cervical cancer stem cells.","authors":"Yi Yang, Li Yu, Jin Li, Ya Hong Yuan, Xiao Li Wang, Shi Rong Yan, Dong Sheng Li, Yan Ding","doi":"10.2147/BTT.S134920","DOIUrl":"https://doi.org/10.2147/BTT.S134920","url":null,"abstract":"Cancer stem cells (CSCs) are a rare population of multipotent cells with the capacity to self-renew. It has been reported that there are CSCs in cervical cancer cells. Pluripotency-associated (PA) transcription factors such as Oct4, Sox2, Nanog and CD44 have been used to isolate CSCs subpopulations. In this study, we showed that autophagy plays an important role in the biological behavior of cervical cancer cells. The expression of the autophagy protein Beclin 1 and LC3B was higher in tumorspheres established from human cervical cancers cell lines (and CaSki) than in the parental adherent cells. It was also observed that the basal and starvation-induced autophagy flux was higher in tumorspheres than in the bulk population. Autophagy could regulate the expression level of PA proteins in cervical CSCs. In addition, CRISPR/Cas 9-mediated Beclin 1 knockout enhanced the malignancy of HeLa cells, leading to accumulation of PA proteins and promoted tumorsphere formation. Our findings suggest that autophagy modulates homeostasis of PA proteins, and Beclin 1 is critical for CSC maintenance and tumor development in nude mice. This demonstrates that a prosurvival autophagic pathway is critical for CSC maintenance.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"11 ","pages":"71-79"},"PeriodicalIF":4.0,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S134920","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35148946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn's disease. 在抗tnf α治疗克罗恩病期间观察到矛盾的SAPHO综合征。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-05-22 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S134508

Hitoshi Amano, Reikei Matsuda, Tomohiko Shibata, Daisuke Takahashi, Shinichiro Suzuki

引用次数: 6

Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties. 开发一种具有预防和治疗双重特性的免疫反应强效刺激剂。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-05-02 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S128308

Gursaran P Talwar, Jagdish C Gupta, Abu S Mustafa, Hemanta K Kar, Kiran Katoch, Shreemanta K Parida, Prabhakara P Reddi, Niyaz Ahmed, Vikram Saini, Somesh Gupta

引用次数: 14

CUL4A promotes cell invasion in gastric cancer by activating the NF-κB signaling pathway. CUL4A通过激活NF-κB信号通路促进胃癌细胞侵袭。

IF 4

Biologics : Targets & Therapy Pub Date : 2017-04-12 eCollection Date: 2017-01-01 DOI: 10.2147/BTT.S127650

Yu Gong, Xiao-Jun Xiang, Miao Feng, Jun Chen, Zi-Ling Fang, Jian-Ping Xiong

{"title":"CUL4A promotes cell invasion in gastric cancer by activating the NF-κB signaling pathway.","authors":"Yu Gong, Xiao-Jun Xiang, Miao Feng, Jun Chen, Zi-Ling Fang, Jian-Ping Xiong","doi":"10.2147/BTT.S127650","DOIUrl":"https://doi.org/10.2147/BTT.S127650","url":null,"abstract":"Cullin 4A (CUL4A) overexpression has been reported to be involved in the carcinogenesis and progression of many malignant tumors. However, the role of CUL4A in the progression of gastric cancer (GC) remains unclear. In this study, we explored whether and how CUL4A regulates proinflammatory signaling to promote GC cell invasion. Our results showed that knockdown of CUL4A inhibited GC cell migration and invasion induced by lipopolysaccharide (LPS) stimulation. We also found that both CUL4A and nuclear factor-kappa B (NF-κB) protein expressions were enhanced by LPS stimulation in HGC27 GC cell lines. Furthermore, knockdown of CUL4A decreased the protein expression of NF-κB and mRNA expression of the downstream genes of the NF-κB pathway, such as matrix metalloproteinase (MMP) 2, MMP9, and interleukin-8. Our immunohistochemistry analysis on 50 GC tissue samples also revealed that CUL4A positively correlated with NF-κB expression. Taken together, our findings suggest that CUL4A may promote GC cell invasion by regulating the NF-κB signaling pathway and could be considered as a potential therapeutic target in patients with GC.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"11 ","pages":"45-53"},"PeriodicalIF":4.0,"publicationDate":"2017-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S127650","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34943956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10